Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database

References

• Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week ran-domized trial comparing methotrexate and auranofin. Arthritis Rheum. 1993;36:613–9.
   PubMed Web of Science ®Google Scholar
• Cannella AC, O'Dell JR. Is there still a role for traditional dis-ease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis? Curr Opin Rheumatol. 2003;15:185–92.
   Google Scholar
• Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis. 2005;64:207–11.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the dose-ranging assessment: international clinical evaluation of rituximab in rheumatoid arthritis (DANCER) trial. J Rheumatol. 2008;35:20–30.
   Google Scholar
• van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction therapy in patients with early rheu-matoid arthritis. Arthritis Rheum. 2007;56:2129–34.
   PubMed Web of Science ®Google Scholar
• Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007;56:1765–75.
   PubMed Web of Science ®Google Scholar
• van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited effi-cacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated accord-ing to the disease activity score. Ann Rheum Dis. 2007; 66:1356–62.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheuma-toid arthritis: two-year clinical and radiographic results from theTEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063–74.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial. Arthritis Rheum. 2005;52:3381–90.
   Google Scholar
• American College of Rheumatology Subcommittee on Rheuma-toid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328–46.
   PubMed Web of Science ®Google Scholar
• Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Meth-otrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173–7.
   PubMed Web of Science ®Google Scholar
• Kashiwazaki S, Ichikawa Y, Sugawara S, Nagaya I, Kawai S, Hakota M, et al. Determination of the clinical optimal dose of L-377 (methotrexate capsule) for the treatment of rheumatoid arthritis. Drug Evaluation. 1996;16:437–58.
   Google Scholar
• Akahoshi T, Ueda H, Kashiwazaki S. Immunosuppressive drugs in the treatment of rheumatoid Arthritis (in Japanese). Saishin Igaku. 1989;44:1918–25.
   Google Scholar
• Ranganathan P, McLeod HL. Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum. 2006;54:1366–77.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
   PubMedGoogle Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Tan-iguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3, 763 patients with rheu-matoid arthritis. Arthritis Rheum. 2003;49: 784–8.
   Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010 (Epub ahead of print PMID: 20476859).
   Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Taniguchi A, Momohara S, et al. Incidence of malignancy in Japanese patients with rheumatoid arthritis. Rheumatol Int. 2010 May 16 (Epub ahead of print PMID: 20473757).
   Google Scholar
• Shidara K, Hoshi D, Inoue E, Yamada T, Nakajima A, Taniguchi A, et al. Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observa-tional cohort, IORRA. Mod Rheumatol. 2010;20:280–6.
   PubMed Web of Science ®Google Scholar
• Momohara S, Inoue E, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, et al. Decrease in orthopaedic operations, including total joint replacements, in patients with rheumatoid arthritis between 2001 and 2007: data from Japanese outpatients in a single institute-based large observational cohort (IORRA). Ann Rheum Dis. 2010;69:312–3.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patient with rheumatoid arthritis during the prebiologics period in Japan: a large pro-spective observational cohort study. Mod Rheumatol. 2010; 20:46–53.
   PubMed Web of Science ®Google Scholar
• Iikuni N, Sato E, Hoshi M, Inoue E, Taniguchi A, Hara M, et al. The influence of sex on patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2009;36:508–11.
   PubMed Web of Science ®Google Scholar
• Momohara S, Ikari K, Mochizuki T, Kawamura K, Tsukahara S, Told H, et al. Declining use of synovectomy surgery for patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2009; 68:291–2.
   PubMed Web of Science ®Google Scholar
• Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Hara M, et al. Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: a prospective observational cohort study. J Bone Miner Metab. 2008;26:499–505.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, et al. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67:1153–8.
   PubMed Web of Science ®Google Scholar
• Shinozaki M, Inoue E, Nakajima A, Hara M, Tomatsu T, Kamatani N, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. Mod Rheumatol. 2007;17:403–8.
   PubMedGoogle Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17: 283–9.
   Google Scholar
• Okamoto H, Koizumi K, Kamitsuji S, Inoue E, Hara M, Tomatsu T, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007; 34:964–8.
   PubMed Web of Science ®Google Scholar
• Likuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M, et al. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology (Oxford). 2007;46:846–8.
   PubMedGoogle Scholar
• Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. Mod Rheumatol. 2006;16:376–80.
   PubMedGoogle Scholar
• Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheuma-tol. 2007;34:303–10.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006;16:214–9.
   PubMedGoogle Scholar
• Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N, et al. Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol. 2006;16:151–7.
   PubMedGoogle Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORP: significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12–9.
   PubMed Web of Science ®Google Scholar
• Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. Mod Rheumatol. 2010 (Epub ahead of print PMID: 20574649).
   Google Scholar
• Hashiramoto A, Shiozawa K, Tanaka Y, Yamane T, Murata M, Tanaka C, et al. Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the gov-ernment recommended 8 mg/week dose. Mod Rheumatol. 2009;19:637–42.
   PubMed Web of Science ®Google Scholar